Literature DB >> 18849185

SPARC in cancer biology: its role in cancer progression and potential for therapy.

Isabella T Tai1, Michelle J Tang.   

Abstract

The ability to effectively target a tumor to achieve complete regression and cure is the ultimate goal that drives our need to better understand tumor biology. Recently, SPARC has generated considerable interest as a multi-faceted protein that belongs to a family of matricellular proteins. It functions not only to modulate cell-cell and cell-matrix interactions, but its de-adhesive and growth inhibitory properties in non-transformed cells have led to studies to assess its role in cancer. Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor. Recent studies have also demonstrated a role for SPARC in sensitizing therapy-resistant cancers. Here, the role of SPARC in cancer progression and its potential application in cancer therapy is discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849185     DOI: 10.1016/j.drup.2008.08.005

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  89 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

2.  Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.

Authors:  Zijun Zhen; Kaibin Yang; Litong Ye; Zhiyao You; Rirong Chen; Ying Liu
Journal:  Invest New Drugs       Date:  2017-06-20       Impact factor: 3.850

3.  SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer.

Authors:  Hong Zhang; Emma Widegren; Da-Wei Wang; Xiao-Feng Sun
Journal:  Tumour Biol       Date:  2011-09-02

Review 4.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 5.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

6.  Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.

Authors:  Jian-fang Liang; Hong-kun Wang; Hong Xiao; Ning Li; Cai-xia Cheng; Yu-ze Zhao; Yan-b Ma; Jian-zhong Gao; Rui-bing Bai; Hui-xia Zheng
Journal:  J Exp Clin Cancer Res       Date:  2010-06-16

7.  Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Authors:  Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Mol Cancer       Date:  2010-06-04       Impact factor: 27.401

8.  Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival.

Authors:  Jie Yin; Guowei Chen; Yucun Liu; Si Liu; Pengyuan Wang; Yuanlian Wan; Xin Wang; Jing Zhu; Hongqiao Gao
Journal:  J Exp Clin Cancer Res       Date:  2010-06-02

9.  Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1.

Authors:  Yong Zhong Xu; Mitra Heravi; Thusanth Thuraisingam; Sergio Di Marco; Thierry Muanza; Danuta Radzioch
Journal:  Mol Cancer       Date:  2010-08-05       Impact factor: 27.401

10.  Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.

Authors:  G Chen; X Tian; Z Liu; S Zhou; B Schmidt; D Henne-Bruns; M Bachem; M Kornmann
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.